GHENT, BELGIUM--(Marketwire - October 20, 2008) - GHENT, Belgium, 20 October, 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that a consortium, comprising DG Infra+, B.S.I. and Foremost Immo, has committed to invest in the development of a 10,000 m2 cutting-edge laboratory facility (the Bio-Accelerator) on the Technologiepark in Zwijnaarde, Ghent. This facility will be close to Ablynx's existing facilities and the company has secured the right to use 70% of the capacity of the Bio-Accelerator, which is expected to be completed by mid-2010.
